No abstract

Objective: To investigate the efficacy of Dr Allen’s Therapeutic Device in improving quality of life in patients with nephrolithiasis.Materials and Methods: A randomized, interventional, parallel group study was conducted investigating 54 patients aged 18-60 years with nephrolithiasis. 29 of the 54 patients were randomised (1:1) into a treatment group of 15 patients (Group 1) and a control group of 14 patients. The remaining 25 (Group 2) were treated but not randomised as they had stones larger than 10 mm. Both treatment groups used Dr Allen’s Device for 6 months. Their quality of life was measured using the Wisconsin Stone Quality of Life Questionnaire (WISQoL) at regular intervals and compared between the groups. The change in size of the kidney stones was also measured and compared. The trial was registered at the World Health Organisation via the German Clinical Trials Registry (DRKS00009367).Results: Thermobalancing therapy with Dr Allen's Device for Kidney Treatment showed a significant improvement in HRQoL across all domains of the WISQoL and a significant reduction in size of kidney stones in both treatment groups (p<0.001). There was no significant change in stone size in the control group. Conclusions: The use of Thermobalancing therapy with Dr Allen's Device for Kidney Treatment is effective in both dissolving kidney stones as well as improving quality of life.

Introduction:The Coronavirus (COVID-19) outbreak has demonstrated the need for a novel delivery of treatment for benign prostate enlargement (BPE) and chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS). Their standard treatments with medications and surgeries require extensive contact between patients and healthcare professionals that worsens a pandemic. This study aims to determine whether therapeutic Dr Allen's Device (DATD) and Thermobalancing therapy (TT) can be used as an effective self-management tool and athome treatment for chronic prostate diseases. Methods: This is a retrospective cohort study of 45 men with CP/CPPS and 124 men with BPE who were observed before and after applying TT with DATD at home for 6 months in 2 clinical controlled trials. The dynamics of clinical characteristics and parameters, such as pain, urinary symptoms, quality of life (QoL), and prostate volume (PV) were compared to the control groups without DATD. Results: DATD reduced pain scores from 10.3 to 3.5 (P<0.001) in men with CP/CPPS. In men with BPE, DATD reduced PV from 45mL to 31mL (P<0.001) and urinary symptoms from 14.3 to 4.9 (P<0.001). DADT significantly improved QoL in both treatment groups. In the control groups, no positive changes were observed. Conclusions: The use of DATD with TT relieves chronic pelvic pain and reduces an abnormal prostate size in patients with CP/CPPS and BPE, improving their QoL and wellbeing. Thus, DATD is an effective at-home self-management tool and provides a novel delivery of treatment for non-cancerous prostatic diseases, especially important during a pandemic.

Background: The choice of treatment for benign prostatic hyperplasia (BPH) and kidney stone disease (KSD) impacts the attainment of successful ageing and the level of patient care required in the long-term. Medications and surgeries typically used for these conditions have serious side effects and can interfere with healthy aging. Objectives: This study assesses the impact of Dr Allen’s Therapeutic devices (DATD) and thermobalancing therapy® (TT) on the ageing process of people with BPH and KSD. Methods: This study evaluated the outcomes of a clinical trial investigating the dynamics of symptoms and parameters in 124 male patients with BPH who used DATD as a monotherapy for six months at home and compared the results with a control group including 124 BPH patients who did not receive treatment with DATD. Furthermore, five case studies were randomly selected for assessment from 10-year empirical observations of patients with KSD treated with DATD. Results: DATD with TT reduced prostate volume (PV) from 45 mL to 31 mL (P < 0.001) and reduced urinary symptoms score from 14.2 to 4.9 (P < 0.001). It also improved quality of life (QoL) as measured by the reduction in the International Prostate Symptom score (I-PSS) from 3.9 to 1.3 (P < 0.001), while the control group showed no positive changes. DATD with TT dissolved kidney stones without renal colic in all patients. No side effects were observed. Conclusions: Using DATD and TT to treat BPH and KSD demonstrated high efficacy, safety, and easy disease management at home. In contrast, medications and surgeries for BPH and KSD often lead to sexual dysfunction, depression, hypertension, chronic kidney failure, and other morbidities, requiring an increased care level in the long-term. Thus, DATD and TT generate high treatment efficacy with lower exposure to coronavirus, reduce long-term care needs, and are vital to attaining successful ageing and longevity.

No abstract